Sarepta (SRPT) - Multiplikator Forward P/S

Logo korporat perusahaan Sarepta Therapeutics (SRPT)

Sarepta Therapeutics, Inc. (SRPT) dominates muscular dystrophy therapy, leveraging exclusive patents and FDA approval to create insurmountable barriers for competitors. The forward P/S ratio visualizes market expectations, where the 0.80 mark characterizes this parameter. Innovative DNA-based drugs ensure a steady cash flow, while a closed diagnostic ecosystem guarantees absolute patient loyalty to the brand's products.

SRPT sarepta.com: Rega forward marang dodolan ing interval 04.07.2022 - 18.11.2026

Rincian metrik keuangan lan pasar Sarepta Therapeutics, Inc. (SRPT)

Analisis wiwitan perusahaan:Sarepta Therapeutics (SRPT)
Produk asli Sarepta Corp

Forward P/S is a key tool for valuing an asset relative to its future cash flows. This metric correlates current market capitalization with projected annual sales volume, filtering out short-term market noise. By analyzing a business's forward P/S, an investor determines the extent of expectations already priced in. For Sarepta Therapeutics, Inc. (SRPT), this reflects the market's bet on the commercial success of Elevidys and the expansion potential of gene therapy.

Pesaing Sarepta Therapeutics, Inc.

Multiplikator Forward P/S TEM (Tempus Labs)|Qiagen N.V. - Rasio rega marang prakiraan pendapatan|IONS - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep repligen.com|RNA: Multiplikator Forward P/S|CRISPR Therapeutics Inc (CRSP) - Multiplikator Forward P/S|WGS (GeneDx Holdings) - Multiplikator Forward P/S|RARE: Rega forward marang dodolan|Multiplikator forward rega marang pendapatan BEAM (Beam Therapeutics Corp)|Twist Bioscience - Kapitalisasi marang prakiraan pendapatan|10x Genomics Inc - Multiplikator forward rega marang pendapatan|NTLA (Intellia Therapeutics, Inc.) - Rega mangsa ngarep marang pendapatan|Stoke Corp - Multiplikator Forward P/S|BLFS (BioLife) - Kapitalisasi marang prakiraan pendapatan|wavelifesciences.com (WVE) - Rasio rega marang prakiraan pendapatan|MAZE - Rasio kapitalisasi marang dodolan sing dikarepake|SION (Sionna Therapeutics, Inc.) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan Prime Medicine Corp (PRME)|Multiplikator Forward P/S TSHA|Multiplikator Forward P/S uniQure N.V. (QURE)|Rasio rega marang prakiraan pendapatan MeiraGTx Holdings plc MGTX|RGNX: Kapitalisasi marang prakiraan pendapatan|Solid Biosciences Inc - Multiplikator Forward P/S|OCGN - Multiplikator Forward P/S|PACB: Multiplikator Forward P/S|BNTC - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan Design Therapeutics, Inc.|RCKT: Rega forward marang dodolan|Multiplikator forward rega marang pendapatan FDMT (4D Molecular Therapeutics, Inc.)|Lexeo Therapeutics, Inc. - Kapitalisasi marang prakiraan pendapatan|Rasio rega marang prakiraan pendapatan Korro Bio, Inc. KRRO|EDIT: Kapitalisasi marang prakiraan pendapatan|SLN - Rasio rega marang prakiraan pendapatan|Prakiraan rega marang pendapatan ProQR Therapeutics (PRQR)|CDXS (Codexis Bio) - Multiplikator forward rega marang pendapatan|Sangamo Therapeutics Inc. (SGMO) - Multiplikator Forward P/S|Rasio rega marang prakiraan pendapatan Nautilus Bio|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Metagenomi Therapeutics MGX|Rasio rega marang prakiraan pendapatan Precision BioSciences (DTIL)|GBIO - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Multiplikator Forward P/S BOLD (Boundless Bio, Inc)|XCUR - Multiplikator forward rega marang pendapatan|IMNN - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Phio Pharmaceuticals Corp|MBIO: Multiplikator Forward P/S|TransCode (RNAZ) - Multiplikator Forward P/S|BNGO (Bionano) - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Applied DNA Sciences, Inc. APDN|Multiplikator Forward P/S BLUE|ImmunoPrecise Antibodies Ltd - Kapitalisasi marang prakiraan pendapatan|Rasio rega marang prakiraan pendapatan Omega Therapeutics OMGA|OMIC: Kapitalisasi marang prakiraan pendapatan|RGLS: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan SYRS (Syros Pharmaceuticals, Inc.)|Telesis Bio, Inc. (TBIO) - Rasio rega marang prakiraan pendapatan|Rega mangsa ngarep marang pendapatan TCON (TRACON)|Rasio rega marang prakiraan pendapatan Unity Biotechnology, Inc.